Payment overview · 2025
General Payments
$15,729.06
163 reported records · 31 companies
Healthcare provider profile · identity verified
Ramesh Gowda, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · NEW YORK, NY · NPI 1073589636
Verified facts
What the public records show
CMS Open Payments records show Ramesh Gowda, MD received $15,729.06 in general payments during 2025 across 163 reported records.
Bard Peripheral Vascular, Inc. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $5,254.89 | 33.4% | 37 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $2,086.38 | 13.3% | 21 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $1,725.06 | 11.0% | 12 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,225.01 | 7.8% | 13 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $714.73 | 4.5% | 12 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $490.50 | 3.1% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $475.40 | 3.0% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$404.58 | 2.6% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $400.14 | 2.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $285.00 | 1.8% | 2 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $259.61 | 1.6% | 4 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $249.14 | 1.6% | 6 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $222.18 | 1.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $210.10 | 1.3% | 3 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $201.02 | 1.3% | 2 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $188.14 | 1.2% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $187.57 | 1.2% | 2 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $182.04 | 1.2% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $162.62 | 1.0% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $144.71 | 0.9% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $127.59 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $122.43 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $113.20 | 0.7% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.31 | 0.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $48.66 | 0.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.25 | 0.2% | 2 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $30.46 | 0.2% | 1 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $30.05 | 0.2% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $24.99 | 0.2% | 1 | 2025 |
| Procyrion, Inc. | Unresolved — no canonical attribution shown | $23.71 | 0.1% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $14.59 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $12,244.40 | 151 |
| Consulting Fee | $2,012.50 | 1 |
| Travel and Lodging | $1,472.16 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $1,801.44 | 18 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc., Davol Inc. | $1,690.99 | 15 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $1,087.67 | 11 | 2025 |
Source payment records
|
|||||
| 2cm Peripheral Cutting Balloon Normalized: 2cm peripheral cutting balloon |
Device | Boston Scientific Corporation | $1,060.73 | 11 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $750.96 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $720.63 | 5 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $720.63 | 5 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $514.85 | 7 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $301.82 | 4 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $288.75 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $285.00 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $284.21 | 3 | 2025 |
Source payment records
|
|||||
| Atlas Normalized: atlas |
Device | Bard Peripheral Vascular, Inc., Davol Inc. | $278.86 | 4 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $259.61 | 4 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $253.88 | 2 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $222.18 | 3 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $219.80 | 3 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $214.89 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $210.10 | 3 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $199.88 | 5 | 2025 |
Source payment records
|
|||||
| COVERA Normalized: covera |
Device | Bard Peripheral Vascular, Inc. | $197.85 | 2 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $182.04 | 1 | 2025 |
Source payment records
|
|||||
| REVCORE THROMBECTOMY CATHETER Normalized: revcore thrombectomy catheter |
Device | Stryker Corporation | $176.81 | 2 | 2025 |
Source payment records
|
|||||
| VENACORE THROMBECTOMY CATHETER Normalized: venacore thrombectomy catheter |
Device | Stryker Corporation | $169.41 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $162.62 | 3 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $161.55 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $159.82 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $146.26 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $142.11 | 1 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $128.19 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $127.59 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $122.43 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $87.31 | 3 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $72.83 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $48.66 | 2 | 2025 |
Source payment records
|
|||||
| MCC Undivided Normalized: mcc undivided |
Device | Philips North America LLC | $44.54 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $44.35 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $38.55 | 1 | 2025 |
Source payment records
|
|||||
| PRESTO Normalized: presto |
Device | Bard Peripheral Vascular, Inc. | $34.31 | 1 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $30.05 | 1 | 2025 |
Source payment records
|
|||||
| FORTREX Normalized: fortrex |
Device | Medtronic, Inc. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $24.54 | 2 | 2025 |
Source payment records
|
|||||
| AORTIX SYSTEM Normalized: aortix system |
Device | Procyrion, Inc. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| NANOCROSS ELITE Normalized: nanocross elite |
Device | Medtronic, Inc. | $11.74 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 5F VCS Normalized: cardiva vascade 5f vcs |
Device | CARDIVA MEDICAL, INC. | $9.71 | 1 | 2025 |
Source payment records
|
|||||
| NITREX Normalized: nitrex |
Device | Medtronic, Inc. | $4.28 | 1 | 2025 |
Source payment records
|
|||||
| Interlock Normalized: interlock |
Device | Boston Scientific Corporation | $2.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 239 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 70 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
125 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 621 | 230 |
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 193 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 533 | 191 |
| Metoprolol Succinate | Metoprolol Succinate | 422 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 106 |
| Ezetimibe | Ezetimibe | 243 | 83 |
| Eliquis | Apixaban | 239 | 70 |
| Losartan Potassium | Losartan Potassium | 201 | 85 |
| Fenofibrate | Fenofibrate Nanocrystallized | 149 | 50 |
| Carvedilol | Carvedilol | 143 | 50 |
| Lisinopril | Lisinopril | 138 | 53 |
| Ramipril | Ramipril | 134 | 50 |
| Entresto | Sacubitril/Valsartan | 125 | 33 |
| Xarelto | Rivaroxaban | 109 | 27 |
| Furosemide | Furosemide | 101 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 93 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 87 | 32 |
| Repatha Sureclick | Evolocumab | 81 | 21 |
| Torsemide | Torsemide | 80 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 19 |
| Eplerenone | Eplerenone | 55 | 18 |
| Nifedipine Er | Nifedipine | 54 | 20 |
| Vascepa | Icosapent Ethyl | 52 | 14 |
| Brilinta | Ticagrelor | 48 | 16 |
| Cilostazol | Cilostazol | 46 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | 12 |
| Folic Acid | Folic Acid | 44 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 20 |
| Valsartan | Valsartan | 43 | 16 |
| Labetalol Hcl | Labetalol Hcl | 42 | 21 |
| Jardiance | Empagliflozin | 41 | 12 |
| Ranolazine Er | Ranolazine | 40 | 14 |
| Enalapril Maleate | Enalapril Maleate | 34 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 11 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 13 |
| Telmisartan | Telmisartan | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Verquvo | Vericiguat | 14 | suppressed |
| Plavix | Clopidogrel Bisulfate | 13 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,729.06 · 163 records | Bard Peripheral Vascular, Inc. | 2cm Peripheral Cutting Balloon, ABRE, AFX2 Bifurcated Endograft System, AORTIX SYSTEM, ARTIX MT, Altius, Alto Abdominal Stent Graft System, Atlas, CAMZYOS, CARDIVA VASCADE 5F VCS, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP XL VVCS 10-12F, CGuard Prime Carotid Stent System, CLOT MANAGEMENT, CLOTTRIEVER BOLD CATHETER, COVERA, CT THROMBECTOMY SYSTEM KIT, Coronary Other, ELIQUIS, ENDURANT IIS, FARXIGA, FFRct, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, FORTREX, FUROSCIX, General - Therapies, HAWKONE, IGT Devices Undivided, Indigo System, Interlock, JARDIANCE, KENGREAL, Kerendia, LEQVIO, LOKELMA, LUTONIX Drug Coated Balloon, MCC Undivided, MYNX CONTROL VENOUS, NANOCROSS ELITE, NITREX, PRESTO, PRODIGY CATHETER, Penumbra System, REPATHA, REVCORE THROMBECTOMY CATHETER, SYMPHONY CATHETER, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TREO ABDOMINAL STENT-GRAFT SYSTEM, ULTREON, VENACORE THROMBECTOMY CATHETER, VERQUVO, Venclose Maven Catheter, Venovo, WAINUA, XIENCE SKYPOINT | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error